FDA to hold public meetings on DTC

Share this article:
The FDA will be seeking comment on the presentation of risk information, the use of certain advertising strategies, comparative DTC promotion and other topics during a public meeting scheduled for Nov. 1 and Nov. 2 in Washington, D.C.
Notice of the meeting was posted in the Federal Register on Sept. 13.
"FDA is interested in hearing whether the indication of a drug or device can be effectively communicated to a lay audience under the confines of DTC promotion," the public notice read. "FDA is also specifically interested in whether paying greater attention to the educational component of an advertisement would help consumers better understand the role drug and device therapy may play in treating the disease."
The agency is also expected to seek comment on whether free samples, coupons and money-back guarantees are promoting undue influence over consumers.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions